Welcome to our dedicated page for Goodrx Holdings news (Ticker: GDRX), a resource for investors and traders seeking the latest updates and insights on Goodrx Holdings stock.
GoodRx Holdings, Inc. operates a digital healthcare platform focused on prescription and medication savings in the United States. Company news commonly covers prescription transaction revenue, retail pharmacy trends, negotiated discount pricing, PBM relationships, and the expansion of Pharma Direct manufacturer programs that connect branded drug discounts to consumers at the pharmacy counter.
GoodRx updates also include self-pay pricing arrangements for GLP-1 and other branded medications, subscription health services such as condition-specific programs, earnings releases, business outlook commentary, and partnerships with pharmaceutical manufacturers, pharmacies, payers, and healthcare professionals.
GoodRx (Nasdaq: GDRX) earned its 2026 HITRUST i1 Certification for its prescription savings platform hosted on Amazon Web Services. The certification validates controls for protecting sensitive healthcare data and risk management across data centers in California, Ohio, Oregon, and Virginia.
The award follows independent third-party testing and signals ongoing investment in cybersecurity and trust for a platform used by nearly 25 million consumers and over one million healthcare professionals annually.
GoodRx (Nasdaq: GDRX) will release its fourth quarter and full year 2025 results after U.S. markets close on Wednesday, February 25, 2026.
Management will host a conference call and webcast on Thursday, February 26, 2026 at 5:00 a.m. PT (8:00 a.m. ET). According to the company, materials and a live webcast will be available at https://investors.goodrx.com, and an archived webcast will be posted for at least 30 days.
Surescripts and GoodRx (GDRX) announced Script Corner, a mobile-friendly patient experience web app that delivers prescription price transparency, including GoodRx discounted cash prices, at the moment a prescriber transmits an eligible e-prescription.
Script Corner will launch with select health systems in Illinois and Texas in late January 2026 and expand more broadly through 2026. Features at launch include insurance copay and GoodRx pricing across all pharmacies by default, secure patient links by text, and future medication management and adherence tools.
GoodRx (Nasdaq: GDRX) launched RxSmartSaver at Giant Eagle pharmacies on January 8, 2026, giving customers instant access to savings on high‑cost brand medications at the pharmacy counter.
The turnkey program offers manufacturer copay cards and nearly 80 unique cash prices, with specific discounted pricing including Ozempic and Wegovy injections at $199/month and the new Wegovy pill at $149/month. RxSmartSaver requires only a QR scan at checkout and is live at more than 200 Giant Eagle pharmacies across Indiana, Maryland, Ohio, Pennsylvania, and West Virginia.
GoodRx (Nasdaq: GDRX) announced the Wegovy® pill (oral semaglutide) is available at a $149/month cash price for the two lowest doses (1.5mg and 4mg) at more than 70,000 pharmacies nationwide through GoodRx, with telemedicine access via GoodRx for Weight Loss to assess eligibility and prescribe when appropriate. The promotional $149 price for 4mg applies through April 15, 2026, then $199/month will apply; 9mg and 25mg doses are $299/month. GoodRx reports nearly 30 million annual consumers and says it has helped save over $85 billion since 2011.
GoodRx (Nasdaq: GDRX) said its executives will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 1:30 p.m. PT (4:30 p.m. ET).
The presentation will cover business updates. A live webcast will be available on the company’s Investor Relations website and an archived recording will be posted on the website for at least 30 days after the event.
GoodRx (Nasdaq: GDRX) launched GoodRx for Weight Loss, a telemedicine subscription for FDA-approved GLP-1 weight-loss care and announced an introductory cash price for Ozempic and Wegovy pens. The subscription is $39/month introductory through January 2026, rising to $119/month on February 1, 2026. GoodRx offers an introductory price of $199/month for the first two fills of the two lowest doses (0.25 mg, 0.5 mg) for Ozempic and Wegovy, moving to $349/month thereafter; self-pay Ozempic 2.0 mg remains $499. Offer valid through March 31, 2026. GoodRx cites nearly 30 million users and $85 billion saved since 2011.
Summary not available.
GoodRx (Nasdaq: GDRX) launched GoodRx for Hair Loss on October 15, 2025, a subscription service for men that bundles a virtual consultation, clinically proven prescription medications, and home delivery.
The service offers prescriptions for oral finasteride or oral minoxidil, guarantees discreet delivery with no fee, and advertises pricing starting at $16/month (final price varies by medication and delivery cadence). GoodRx positions the product as a simpler, lower-cost alternative to multi‑step kits and highlights its platform scale: nearly 30 million consumers and over $85 billion saved since 2011.
GoodRx (Nasdaq: GDRX) will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025.
The company will host a conference call and webcast to discuss results and outlook on Wednesday, November 5, 2025 at 5:00 a.m. PT (8:00 a.m. ET). Telephone participants should call (800) 715-9871 at least 10 minutes early and use conference ID 9085550. The live webcast and accompanying materials will be available on the company investor relations site at https://investors.goodrx.com, with an archived recording posted for at least 30 days approximately one hour after the call.